港股異動丨歌禮制藥-B(1672.HK)大漲逾13% 與頂級投資機構一同參與Sagimet 8000萬美元交叉輪融資
格隆匯2月16日丨歌禮制藥-B(1672.HK)高開高走,現大漲逾13%,報3.34港元,總市值36.7億港元。歌禮制藥-B(01672.HK)宣佈,公司作為現有投資者,通過其全資子公司AP1 1Limited(以下簡稱AP11)參與Sagimet 8,000萬美元交叉輪融資。該輪融資由一家未披露的醫療健康投資基金領投,其他新進投資者Altium、HMCapital、Invus和PFM跟投,其它現有投資者Kleiner Perkins、New Enterprise Associates (NEA)和Rock Springs繼續參與本輪融資。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.